Jason Haas
Director at Ligand Pharmaceuticals Inc (LGND); CFO at Odyssey Therapeutics, Inc. (ODTX)
Purchase track record
Not enough history. Based on 1 purchase with a full 90 days of price history.
—
Avg. 90-day return+27.0%
vs. S&P 500+22.2%
Beat the market100%
Paper profit on buys−$1K
Total bought / sold$20K / $3.7M
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Aug 14SEC | LGNDLigand Pharmaceuticals Inc | Sell | 7,1383,981 held (−64%) | $292.81 | $2.1M | +3.1% |
| Jun 15SEC | LGNDLigand Pharmaceuticals Inc | Sell | 3,0008,442 held (−26%) | $255.01 | $765K | +18.4% |
| Jun 15SEC | LGNDLigand Pharmaceuticals Inc | Sell | 3,4614,981 held (−41%) | $256.08 | $886K | +17.9% |
| May 11SEC | ODTXOdyssey Therapeutics, Inc. | Buy | 1,00062,908 held (+2%) | $20.00 | $20K | -5.0% |
- Sell
Director Jason Haas sold $2.1M of LGND at $292.81 — cuts the stake by 64%.
- Sell
Director Jason Haas sold $765K of LGND at $255.01 — cuts the stake by 26%.
- Sell
Director Jason Haas sold $886K of LGND at $256.08 — cuts the stake by 41%.
- Buy
CFO Jason Haas bought $20K of ODTX at $20.00 — first open-market purchase in our records.